Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

TKI discontinuation proved to be safe and feasible in patients with CML with deep and
durable molecular responses, introducing an additional treatment goal for these patients …

Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic
myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR …

Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in
such a way that patients with adequate access to these agents, who are properly managed …

Chronic myeloid leukemia is a malignancy of bone marrow that affects white blood cells.
There is strong evidence that disease progression, treatment responses, and overall clinical …

The treatment of chronic myeloid leukemia (CML) has been radically changed by the
approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is …

Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase
chronic myeloid leukemia (CP‐CML) after treatment discontinuation (TD) has never been …

In 2022, the obtention of sustained deep molecular response (DMR) with successful
subsequent treatment-free remission (TFR) is part of the new paradigm of treatment of …

The advent of tyrosine kinase inhibitors (TKIs) has dramatically improved the outcome of
patients with chronic myeloid leukemia (CML). Currently, four TKIs are available for the …